Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications

Stem Cell Reviews and Reports

Volumn 13, Issue 1, 2017, Pages 7-16

  Yoshihara, Masahito ^a,b   Hayashizaki, Yoshihide ^a   Murakawa, Yasuhiro ^a  

^a RIKEN   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical application; Genomic instability; iPSCs; Mutation; Regenerative medicine

Indexed keywords

DNA METHYLTRANSFERASE 3B; PROTEIN BCL 2; TRANSCRIPTION FACTOR;

ALLOTRANSPLANTATION; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIATION; GENOMIC INSTABILITY; INDUCED PLURIPOTENT STEM CELL; NEXT GENERATION SEQUENCING; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; BIOLOGICAL MODEL; CYTOLOGY; GENETICS; HUMAN; METABOLISM; PROCEDURES; RISK FACTOR; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; GENETIC VARIATION; GENOMIC INSTABILITY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, GENETIC; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSCRIPTION FACTORS;

EID: 84984903623     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-016-9680-6     Document Type: Review

References (119)

1. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
2. Yu, J., Vodyanik, M. A., Smuga-Otto, K., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.
3. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872.
4. Avior, Y., Sagi, I., & Benvenisty, N. (2016). Pluripotent stem cells in disease modelling and drug discovery. Nature Reviews. Molecular Cell Biology, 17(3), 170–182.
5. Robinton, D. A., & Daley, G. Q. (2012). The promise of induced pluripotent stem cells in research and therapy. Nature, 481(7381), 295–305.
6. Araki, R., Uda, M., Hoki, Y., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 494(7435), 100–104.
7. Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 12(4), 407–412.
8. Cyranoski, D. (2014). Japanese woman is first recipient of next-generation stem cells. Nature. doi:10.1038/nature.2014.15915.
9. Chakradhar, S. (2016). An eye to the future: Researchers debate best path for stem cell-derived therapies. Nature Medicine, 22(2), 116–119.
10. Garber, K. (2015). RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nature Biotechnology, 33(9), 890–891.
11. Yunis, J. J. (1976). High resolution of human chromosomes. Science, 191(4233), 1268–1270.
12. Meisner, L. F., & Johnson, J. A. (2008). Protocols for cytogenetic studies of human embryonic stem cells. Methods, 45(2), 133–141.
13. Kallioniemi, A., Kallioniemi, O. P., Sudar, D., et al. (1992). Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258(5083), 818–821.
14. Wang, D. G., Fan, J. B., Siao, C. J., et al. (1998). Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science, 280(5366), 1077–1082.
15. Le Scouarnec, S., & Gribble, S. M. (2012). Characterising chromosome rearrangements: recent technical advances in molecular cytogenetics. Heredity, 108(1), 75–85.
16. Riegel, M. (2014). Human molecular cytogenetics: from cells to nucleotides. Genetics and Molecular Biology, 37(1 Suppl), 194–209.
17. Metzker, M. L. (2010). Sequencing technologies - the next generation. Nature Reviews. Genetics, 11(1), 31–46.
18. Pagnamenta, A. T., Lise, S., Harrison, V., et al. (2012). Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. Journal of Human Genetics, 57(1), 70–72.
19. Mayshar, Y., Ben-David, U., Lavon, N., et al. (2010). Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell, 7(4), 521–531.
20. Taapken, S. M., Nisler, B. S., Newton, M. A., et al. (2011). Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nature Biotechnology, 29(4), 313–314.
21. Martins-Taylor, K., Nisler, B. S., Taapken, S. M., et al. (2011). Recurrent copy number variations in human induced pluripotent stem cells. Nature Biotechnology, 29(6), 488–491.
22. Laurent, L. C., Ulitsky, I., Slavin, I., et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell, 8(1), 106–118.
23. McIntyre, A., Summersgill, B., Lu, Y. J., et al. (2007). Genomic copy number and expression patterns in testicular germ cell tumours. British Journal of Cancer, 97(12), 1707–1712.
24. Reuter, V. E. (2005). Origins and molecular biology of testicular germ cell tumors. Modern Pathology, 18(Suppl 2), S51–S60.
25. Lund, R. J., Narva, E., & Lahesmaa, R. (2012). Genetic and epigenetic stability of human pluripotent stem cells. Nature Reviews Genetics, 13(10), 732–744.
26. Chin, M. H., Mason, M. J., Xie, W., et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell, 5(1), 111–123.
27. Elliott, A. M., Elliott, K. A., & Kammesheidt, A. (2010). High resolution array-CGH characterization of human stem cells using a stem cell focused microarray. Molecular Biotechnology, 46(3), 234–242.
28. Guled, M., Myllykangas, S., Frierson, H. F., Jr., Mills, S. E., Knuutila, S., & Stelow, E. B. (2008). Array comparative genomic hybridization analysis of olfactory neuroblastoma. Modern Pathology, 21(6), 770–778.
29. Scotto, L., Narayan, G., Nandula, S. V., et al. (2008). Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes, Chromosomes and Cancer, 47(9), 755–765.
30. Hussein, S. M., Batada, N. N., Vuoristo, S., et al. (2011). Copy number variation and selection during reprogramming to pluripotency. Nature, 471(7336), 58–62.
31. Abyzov, A., Mariani, J., Palejev, D., et al. (2012). Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature, 492(7429), 438–442.
32. Liang, G., & Zhang, Y. (2013). Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell, 13(2), 149–159.
33. Cheng, L., Hansen, N. F., Zhao, L., et al. (2012). Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell, 10(3), 337–344.
34. Gore, A., Li, Z., Fung, H. L., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature, 471(7336), 63–67.
35. Ji, J., Ng, S. H., Sharma, V., et al. (2012). Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells, 30(3), 435–440.
36. Ruiz, S., Gore, A., Li, Z., et al. (2013). Analysis of protein-coding mutations in hiPSCs and their possible role during somatic cell reprogramming. Nature Communications, 4, 1382.
37. Johannesson, B., Sagi, I., Gore, A., et al. (2014). Comparable frequencies of coding mutations and loss of imprinting in human pluripotent cells derived by nuclear transfer and defined factors. Cell Stem Cell, 15(5), 634–642.
38. Quinlan, A. R., Boland, M. J., Leibowitz, M. L., et al. (2011). Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell, 9(4), 366–373.
39. Howden, S. E., Gore, A., Li, Z., et al. (2011). Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proceedings of the National Academy of Sciences of the United States of America, 108(16), 6537–6542.
40. Young, M. A., Larson, D. E., Sun, C. W., et al. (2012). Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell, 10(5), 570–582.
41. Sugiura, M., Kasama, Y., Araki, R., et al. (2014). Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells. Stem Cell Reports, 2(1), 52–63.
42. Hudson, T. J., Anderson, W., Artez, A., et al. (2010). International network of cancer genome projects. Nature, 464(7291), 993–998.
43. Weinstein, J. N., Collisson, E. A., Mills, G. B., et al. (2013). The cancer genome atlas Pan-cancer analysis project. Nature Genetics, 45(10), 1113–1120.
44. Forbes, S. A., Beare, D., Gunasekaran, P., et al. (2015). COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Research, 43(Database issue), D805–D811.
45. Gonzalez-Perez, A., Mustonen, V., Reva, B., et al. (2013). Computational approaches to identify functional genetic variants in cancer genomes. Nature Methods, 10(8), 723–729.
46. Meyerson, M., Gabriel, S., & Getz, G. (2010). Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics, 11(10), 685–696.
47. Watson, I. R., Takahashi, K., Futreal, P. A., & Chin, L. (2013). Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 14(10), 703–718.
48. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews. Cancer, 3(6), 453–458.
49. Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68(4), 820–823.
50. Berger, A. H., Knudson, A. G., & Pandolfi, P. P. (2011). A continuum model for tumour suppression. Nature, 476(7359), 163–169.
51. Yasuda, T., Ueno, T., Fukumura, K., et al. (2014). Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia, 28(2), 426–428.
52. Consortium E.P. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature, 489(7414), 57–74.
53. Fredriksson, N. J., Ny, L., Nilsson, J. A., & Larsson, E. (2014). Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 46(12), 1258–1263.
54. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C., & Lee, W. (2014). Genome-wide analysis of noncoding regulatory mutations in cancer. Nature Genetics, 46(11), 1160–1165.
55. Melton, C., Reuter, J. A., Spacek, D. V., & Snyder, M. (2015). Recurrent somatic mutations in regulatory regions of human cancer genomes. Nature Genetics, 47(7), 710–716.
56. Farh, K. K., Marson, A., Zhu, J., et al. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature, 518(7539), 337–343.
57. Murakawa, Y., Yoshihara, M., Kawaji, H., et al. (2016). Enhanced identification of transcriptional enhancers provides mechanistic insights into diseases. Trends in Genetics, 32(2), 76–88.
58. Bhutani, K., Nazor, K. L., Williams, R., et al. (2016). Whole-genome mutational burden analysis of three pluripotency induction methods. Nature Communications, 7, 10536.
59. Loh, Y. H., Agarwal, S., Park, I. H., et al. (2009). Generation of induced pluripotent stem cells from human blood. Blood, 113(22), 5476–5479.
60. Merling, R. K., Sweeney, C. L., Choi, U., et al. (2013). Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood, 121(14), e98–e107.
61. Ye, Z., Zhan, H., Mali, P., et al. (2009). Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood, 114(27), 5473–5480.
62. Staerk, J., Dawlaty, M. M., Gao, Q., et al. (2010). Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell, 7(1), 20–24.
63. Okita, K., Yamakawa, T., Matsumura, Y., et al. (2013). An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells, 31(3), 458–466.
64. Su, R. J., Baylink, D. J., Neises, A., et al. (2013). Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. PLoS One, 8(5), e64496.
65. Xue, Y., Cai, X., Wang, L., et al. (2013). Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells. PLoS One, 8(8), e70573.
66. Aasen, T., Raya, A., Barrero, M. J., et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotechnology, 26(11), 1276–1284.
67. Oda, Y., Yoshimura, Y., Ohnishi, H., et al. (2010). Induction of pluripotent stem cells from human third molar mesenchymal stromal cells. Journal of Biological Chemistry, 285(38), 29270–29278.
68. Garinis, G. A., van der Horst, G. T., Vijg, J., & Hoeijmakers, J. H. (2008). DNA damage and ageing: new-age ideas for an age-old problem. Nature Cell Biology, 10(11), 1241–1247.
69. Martincorena, I., Roshan, A., Gerstung, M., et al. (2015). Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science, 348(6237), 880–886.
70. Jaiswal, S., Fontanillas, P., Flannick, J., et al. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488–2498.
71. Genovese, G., Kahler, A. K., Handsaker, R. E., et al. (2014). Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New England Journal of Medicine, 371(26), 2477–2487.
72. Kang, E., Wang, X., Tippner-Hedges, R., et al. (2016). Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell, 18(5), 625–636.
73. Wang, B., Miyagoe-Suzuki, Y., Yada, E., et al. (2011). Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Currents, 3, Rrn1274.
74. Rocha, V., Labopin, M., Sanz, G., et al. (2004). Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. New England Journal of Medicine, 351(22), 2276–2285.
75. Haase, A., Olmer, R., Schwanke, K., et al. (2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell, 5(4), 434–441.
76. Giorgetti, A., Montserrat, N., Aasen, T., et al. (2009). Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell, 5(4), 353–357.
77. Su, R. J., Yang, Y., Neises, A., et al. (2013). Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells. PLoS One, 8(4), e59908.
78. Blair, N. F., & Barker, R. A. (2016). Making it personal: the prospects for autologous pluripotent stem cell-derived therapies. Regenerative Medicine, 11(5), 423–425.
79. de Rham, C., & Villard, J. (2014). Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. Journal of Immunology Research, 2014, 518135.
80. Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell, 11(2), 147–152.
81. Nakajima, F., Tokunaga, K., & Nakatsuji, N. (2007). Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells, 25(4), 983–985.
82. Broxmeyer, H. E. (2010). Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell, 6(1), 21–24.
83. Solomon, S., Pitossi, F., & Rao, M. S. (2015). Banking on iPSC--is it doable and is it worthwhile. Stem Cell Reviews, 11(1), 1–10.
84. Baum, C., von Kalle, C., Staal, F. J., et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Molecular Therapy, 9(1), 5–13.
85. Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313–317.
86. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949–953.
87. Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., & Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(8), 348–362.
88. Yu, J., Hu, K., Smuga-Otto, K., et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324(5928), 797–801.
89. Okita, K., Matsumura, Y., Sato, Y., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nature Methods, 8(5), 409–412.
90. Zhou, H., Wu, S., Joo, J. Y., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4(5), 381–384.
91. Kim, D., Kim, C. H., Moon, J. I., et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 4(6), 472–476.
92. Warren, L., Manos, P. D., Ahfeldt, T., et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618–630.
93. Rais, Y., Zviran, A., Geula, S., et al. (2013). Deterministic direct reprogramming of somatic cells to pluripotency. Nature, 502(7469), 65–70.
94. Jiang, J., Lv, W., Ye, X., et al. (2013). Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation. Cell Research, 23(1), 92–106.
95. Ruiz, S., Lopez-Contreras, A. J., Gabut, M., et al. (2015). Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells. Nature Communications, 6, 8036.
96. Gidekel, S., Pizov, G., Bergman, Y., & Pikarsky, E. (2003). Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell, 4(5), 361–370.
97. Almstrup, K., Hoei-Hansen, C. E., Wirkner, U., et al. (2004). Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Research, 64(14), 4736–4743.
98. Boumahdi, S., Driessens, G., Lapouge, G., et al. (2014). SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature, 511(7508), 246–250.
99. Rowland, B. D., & Peeper, D. S. (2006). KLF4, p21 and context-dependent opposing forces in cancer. Nature Reviews. Cancer, 6(1), 11–23.
100. Pelengaris, S., Khan, M., & Evan, G. (2002). c-MYC: more than just a matter of life and death. Nature Reviews. Cancer, 2(10), 764–776.
101. Hart, A. H., Hartley, L., Parker, K., et al. (2005). The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer, 104(10), 2092–2098.
102. West, J. A., Viswanathan, S. R., Yabuuchi, A., et al. (2009). A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature, 460(7257), 909–913.
103. Hou, P., Li, Y., Zhang, X., et al. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science, 341(6146), 651–654.
104. Gurdon, J. B. (1962). Adult frogs derived from the nuclei of single somatic cells. Developmental Biology, 4, 256–273.
105. Chung, Y. G., Eum, J. H., Lee, J. E., et al. (2014). Human somatic cell nuclear transfer using adult cells. Cell Stem Cell, 14(6), 777–780.
106. Ma, H., Morey, R., O'Neil, R. C., et al. (2014). Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature, 511(7508), 177–183.
107. Egli, D., Chen, A. E., Saphier, G., et al. (2011). Reprogramming within hours following nuclear transfer into mouse but not human zygotes. Nature Communications, 2, 488.
108. Liu, P., Kaplan, A., Yuan, B., Hanna, J. H., Lupski, J. R., & Reiner, O. (2014). Passage number is a major contributor to genomic structural variations in mouse iPSCs. Stem Cells, 32(10), 2657–2667.
109. Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016). Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics, 17(6), 333–351.
110. Kawamata, S., Kanemura, H., Sakai, N., Takahashi, M., & Go, M. J. (2015). Design of a tumorigenicity test for induced pluripotent stem cell (iPSC)-derived cell products. Journal of Clinical Medicine, 4(1), 159–171.
111. Nori, S., Okada, Y., Nishimura, S., et al. (2015). Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Reports, 4(3), 360–373.
112. Jaffe, G. J., & Caprioli, J. (2004). Optical coherence tomography to detect and manage retinal disease and glaucoma. American Journal of Ophthalmology, 137(1), 156–169.
113. Fujimoto, J. G., Pitris, C., Boppart, S. A., & Brezinski, M. E. (2000). Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia (New York, NY), 2(1-2), 9–25.
114. Lee, M. O., Moon, S. H., Jeong, H. C., et al. (2013). Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proceedings of the National Academy of Sciences of the United States of America, 110(35), E3281–E3290.
115. Tang, C., Lee, A. S., Volkmer, J. P., et al. (2011). An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology, 29(9), 829–834.
116. Takebe, T., Sekine, K., Enomura, M., et al. (2013). Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature, 499(7459), 481–484.
117. Taguchi, A., Kaku, Y., Ohmori, T., et al. (2014). Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell, 14(1), 53–67.
118. Hayashi, R., Ishikawa, Y., Sasamoto, Y., et al. (2016). Co-ordinated ocular development from human iPS cells and recovery of corneal function. Nature, 531(7594), 376–380.
119. Okano, H., & Yamanaka, S. (2014). iPS cell technologies: significance and applications to CNS regeneration and disease. Molecular Brain, 7, 22.